RCTs supporting ACS guidelines lack representativeness of the diverse ACS population, highlighting a need for more inclusive trial designs.
Randomised clinical trials supporting CPGs for ACS are not fully representative of the diversity of the ACS population and their current standard of care. While some of these issues with representativeness may be explained by how evidence has been accrued over time, efforts should be made by trialists to ensure that the evidence supporting CPGs is representative of the wider ACS population.
Mas-Lladó et al. (Wed,) studied this question.